12-12-2019 дата публикации
Номер: US20190375850A1
The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity. 149.-. (canceled)50. A pluripotent stem cell that comprises a rearranged T-cell receptor (TCR) locus and expresses a chimeric antigen receptor (CAR) , wherein the pluripotent stem cell is derived from a T cell.51. The pluripotent stem cell of claim 50 , wherein (i) the pluripotent stem cell is transduced with the CAR; (ii) pluripotent stem cell does not express TCR on the cell surface; and/or (iii) said CAR binds to a tumor antigen.52. The pluripotent stem cell of claim 51 , wherein said tumor antigen is selected from the group consisting of carbonic anhydrase IX (CA1X) claim 51 , carcinoembryonic antigen (CEA) claim 51 , CD5 claim 51 , CD7 claim 51 , CD10 claim 51 , CD19 claim 51 , CD20 claim 51 , CD22 claim 51 , CD30 claim 51 , CD33 claim 51 , CD34 claim 51 , CD38 claim 51 , CD41 claim 51 , CD44 claim 51 , CD49f claim 51 , CD56 claim 51 , CD74 claim 51 , CD123 claim 51 , CD133 claim 51 , CD138 claim 51 , an antigen of a cytomegalovirus (CMV) infected cell (e.g. claim 51 , a cell surface antigen) claim 51 , epithelial glycoprotein2 (EGP 2) claim 51 , epithelial glycoprotein-40 (EGP-40) claim 51 , epithelial cell adhesion molecule (EpCAM) claim 51 , receptor tyrosine-protein kinases erb-B2 claim 51 ,3 claim 51 ,4 claim 51 , folate-binding protein (FBP) claim 51 , fetal acetylcholine receptor (AChR) claim 51 , folate receptor-a claim 51 , ...
Подробнее